Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-03-02
1996-04-30
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A01N 4338
Patent
active
055125930
ABSTRACT:
A new composition and method of treating depression includes administering to a depressed patient a pharmacologically effective dose of naloxone or naltrexone or their pharmacologically effective salts and esters in combination with at least one nontricyclic serotonin reuptake inhibitor antidepressant or their pharmacologically effective salts and esters. The patient may while undergoing antidepressant therapy be undergoing treatment with a benzodiazepine for anxiety.
REFERENCES:
patent: 5028612 (1991-07-01), Glover
patent: 5064834 (1991-11-01), Zimmerman et al.
American Psychiatric Assoc., Diagnostic & Statistical manual of Mental Disorders III APA, Wash., D.C. (1980), pp. 205-239.
American Psychiatric Assoc., Diagnostic & Statistical Manual of Mental disorders IV APA, Wash., D.C. (1993), pp. 317-350 & 424-429.
American Psychiatric Assoc., Practice Guidelines for Major Depressive Disorder in Adults, Am. J. Psychiatry, vol. 150:4, Apr. 1993 Suppl., pp. 1-26.
Reist et al., A Controlled Trial of Desipramine in 18 Men With Posttraumatic Stress Disorder, Am. J. Psychiatry, vol. 146:4, Apr. 1989, pp. 513-516.
Terenius et al., Naloxone Treatment in Depression: clinical Observations and Effect Psychopharmacolgy, vol. 54, 31-33 (1977).
Dave et al., Intravenous Naloxone Administration in Schizophrenia and Affective . . . Science, vol. 197, 74-76 (1977).
Cohen et al., High Dose Naloxone in Depression Biological Psychiatry, vol. 19, No. 6, 825-832 (1984).
Cohen et al., High Dose Naloxone Infusions in Normals Archives of General Psychiatry, vol. 40, 613-619 (1983).
Mendelson et al., Effects of Naltrexone On Mood And Neuroendocrine Function . . . Psychoneuroendocrinology, vol. 3, 231-236 (1979).
Hollister et al., Aversive Effects of Naltrexone In Subjects Not Dependent On . . . Drug and Alcohol Dependence, vol. 8, 37-41 (1981).
Crowley et al., Naltrexone-Induced Dysphoria in Former Opioid Addicts American J. of Psychiatry, vol. 142, No. 9, 1081-1084, (1985).
Greenstein et al., Naltrexone: A clinical Perspective J. of Clinical Psychiatry, vol. 45, No. 9, 26-28 (1984).
Whitehouse et al., Opioid Antagonists Overcome the Learned Helplessness Effect but Impair Competent Escape Behavior, Physiology & Behavior, vol. 30, 731-734 (1983).
Mucha, Ronald F., High-Dose Oral Naltrexone: Aversive Response in Drug Naive Rat Biological Psychiatry, vol. 27, 543-545 (1990).
Devoize et al., Influence of Naloxone on Antidepressant Drug Effects in the Forced Swimming Test in Mice, Psychopharmacology, vol. 84, 71-75 (1984).
Cintins Marianne M.
MacMillan Keith
Nagle John S.
Nagle John S.
LandOfFree
Composition and method of treating depression using natoxone or does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method of treating depression using natoxone or , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method of treating depression using natoxone or will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-629101